logo
Why the digital services tax had to die for the Canada-U.S. trade deal to live

Why the digital services tax had to die for the Canada-U.S. trade deal to live

Yahoo02-07-2025
WASHINGTON, D.C. — Ottawa could almost taste the tax revenues.
For nearly five years, Canada has been planning a digital services tax (DST) that would generate billions in revenue by taxing large tech firms on their Canadian digital revenues. Just hours before the first DST payments were due on Monday, however, Prime Minister Mark Carney's government called the whole thing off.
Carney's move late Sunday was a capitulation to the White House — and he had little choice after President Donald Trump abruptly cancelled trade negotiations on Friday over the DST, calling it 'a direct and blatant attack on our country.'
Faced with 25 per cent tariffs on most Canadian exports to the U.S. and 50 per cent tariffs on its steel and aluminum, Canada needed to keep the trade talks alive. So Carney did what had to be done, stating that the move 'will support a resumption of negotiations toward the July 21, 2025, timeline set out at this month's G7 Leaders' Summit in Kananaskis.'
The Liberals introduced the DST in 2020 — a three per cent tax on big tech companies with Canadian digital revenues above $20 million per year — as a stopgap, with the real goal of pushing for a multilateral, OECD-led overhaul of the international tax system to curb multinational tax avoidance.
Several countries, including France, the United Kingdom, Italy and Spain, had begun implementing DSTs in 2019 and 2020, raising alarm bells for large U.S. tech firms and advocacy groups.
The Computer & Communications Industry Association (CCIA), a U.S.-based trade association representing technology and communications companies, was one that pushed back, calling the DSTs discriminatory. The taxes 'hit U.S. companies but are designed to exempt local companies, putting U.S. firms at a competitive disadvantage in the market,' said Jonathan McHale, VP of digital trade at CCIA.
President Joe Biden supported an OECD approach to reforming the international tax system — and its moratorium halting the rollout of unilateral DSTs, adopted by the OECD/G20 Inclusive Framework in late 2021. Canada waited in hopes of there being an international tax reform, but by July 11, 2023, when the OECD agreed to another year-long extension on the moratorium, Prime Minister Justin Trudeau's government decided it had waited long enough. It pushed ahead unilaterally to pass the Digital Services Tax Act last summer, despite warnings from U.S. diplomats and risk experts that it could spark a trade war.
While Canada's approach was meant to tax both foreign and domestic firms, McHale said that's simply how countries go about saying they are not formally targeting American companies. He referred to 'disguised techno-trade' and proportionality, noting that 'on the surface, (the DST) looks neutral, but the impact is essentially focused on a particular foreign country.' Canada's DST, he said, would've mostly impacted U.S. tech firms.
But there was opposition to it at home, too, he noted, because the tax would have hurt would-be startups trying to establish themselves in the Canadian market.
'There were lots of Canadian companies that were vocal in their opposition to this, the Canadian Chamber of Commerce chief among them,' he said, noting that they didn't want it to upset their strong startup culture and digital economy.
Biden's team pushed back last year when the tax was passed, arguing repeatedly for a multilateral solution, and then-U.S. Ambassador to Canada David Cohen labelled it 'discriminatory.'
Trump, in turn, had more leverage and threatened the cessation of trade talks and even higher tariffs, but many saw this coming.
'If you don't push back against Canada's (DST), isn't that a green light for other countries to move ahead?' asked McHale. Opposition to DSTs has been a 'longstanding bipartisan issue' in the U.S., he noted.
It can't hurt. Besides, it was necessary to get back to the negotiating table.
After Canada rescinded the tax, Trump and Carney agreed to resume trade talks with an eye toward reaching a deal by July 21. 'Canada's preference has always been a multilateral agreement related to digital services taxation,' Carney's statement said, reminding folks that the DST was only ever meant to be a short-term solution.
His government also remains 'engaged in discussions with the U.S. and other countries to find a workable solution on international taxation that achieves our common objectives,' a Department of Finance official told National Post.
The Canada Revenue Agency issued a statement on Monday confirming the tax was suspended and noting that reimbursements will be made to companies that already paid 'if legislation is tabled in Parliament and receives royal assent.'
The White House, meanwhile, viewed the decision to drop the DST as positive. Trump officials also hope the move will encourage other countries to eliminate similar taxes to avoid U.S. retaliation.
Canada's DST 'would've been the most burdensome tax for U.S. companies — topping the list of revenues extracted from U.S. firms,' McHale said.
But DSTs are still in effect in several countries that have strong trade links with the U.S., including the U.K., Spain and France, and they should expect similar pushback from Washington.
'The U.S. government has been pretty clear that they oppose the policy … so it stands to reason that it would push back against these others as well,' McHale said.
France and Spain are still working to secure a favourable trade agreement with the U.S.. Although the U.K. managed to forge a deal last month, the Trump administration has publicly stated that getting Britain to rescind its DST remains a top priority.
In the meantime, while Ottawa may be left thirsty for big tech revenues, U.S.-Canada trade relations are finally getting a much-needed drink.
National Post
Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark nationalpost.com and sign up for our politics newsletter, First Reading, here.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Deutsche Telekom partnering with Nvida, Brookfield on AI data centre -CEO
Deutsche Telekom partnering with Nvida, Brookfield on AI data centre -CEO

Yahoo

timea few seconds ago

  • Yahoo

Deutsche Telekom partnering with Nvida, Brookfield on AI data centre -CEO

(Reuters) -Deutsche Telekom is partnering with Nvidia and Canadian private equity fund Brookfield in a bid to build one of the EU's AI "gigafactories" in North Rhine-Westphalia, Germany, its chief executive said on Thursday. "We have partnerships with Brookfield and also with Nvidia – these are our big partners for this gigabit factory," CEO Tim Hoettges said in a call with reporters following the company's second quarter results. Although discussions with North Rhine-Westphalia about building the data processing center in the state are ongoing, a final decision has yet to be made. "This is where we currently see our factory. But, of course, that could still change during the selection process," Hoettges said, adding that the company would proceed as quickly as possible once a decision is reached. The company is looking at existing production sites where electricity and water regulatory approvals are already in place, Hoettges said. "Discussions are happening here, for example with RWE," he said. In May, the Bonn-based company said it had teamed up with SAP, web hosting firm Ionos, and unlisted retailer Schwarz, but in June it was reported the companies would submit separate EU bids instead. Hoettges dismissed media reports that it had been in talks to join such a consortium. "It's a good thing that there is competition in Germany," he said. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Cizzle Brands Announces Appointment of Retired NFL Star, Ndamukong Suh, to the Board of Directors
Cizzle Brands Announces Appointment of Retired NFL Star, Ndamukong Suh, to the Board of Directors

Business Wire

time32 minutes ago

  • Business Wire

Cizzle Brands Announces Appointment of Retired NFL Star, Ndamukong Suh, to the Board of Directors

TORONTO--(BUSINESS WIRE)-- Cizzle Brands Corporation (Cboe Canada: CZZL) (OTCQB: CZZLF) (Frankfurt: 8YF) (the 'Company' or 'Cizzle Brands'), is pleased to announce retired NFL Star, Ndamukong Suh, has joined its Board of Directors effective as of August 7, 2025. Suh is a Super Bowl winning, three-time First-Team All-Pro and five-time Pro Bowler who spent 13 seasons in the National Football League with the Detroit Lions, Miami Dolphins, Los Angeles Rams, Tampa Bay Buccaneers, and Philadelphia Eagles. A graduate of the University of Nebraska-Lincoln with a degree in construction management, Suh is the managing partner of House of Spears Management, a family office that has invested in more than 30 companies (including health-tech leader Oura) and operates a growing real-estate development portfolio. In July 2025, Mr. Suh launched the 'No Free Lunch' podcast, sharing insights on wealth building and financial literacy for athletes and entrepreneurs. Also joining the Company's Board of Directors are Michael Doolan and Geoff Bedford. Michael Doolan has over 35 years of experience in all aspects of financial management, with specific expertise in international mergers and acquisitions, offshore financing structures, and international treasury management. He has extensive experience as both a board member and an executive for private and public companies in several industries. Doolan most recently retired as Executive Vice President, Finance and Chief Financial Officer of Neo Performance Materials. Prior to that, he served as Senior Vice President and Chief Financial Officer of Falconbridge Limited of Toronto before its merger with Noranda. Geoff Bedford has held several C-suite positions for publicly traded companies over the last 20 years, and presently serves as Non-Executive Chairman at B.E.S.T Venture Opportunities Fund. He has led innovation in high-growth sectors navigating complex regulatory environments across North America, Europe, and Asia, leveraging his expertise in strategic planning, global operations, and capital markets. Mr. Bedford is a Canadian Chartered Accountant who has completed Harvard Business School's Making Corporate Boards More Effective program. Mr. Bedford holds a Bachelor of Science from the University of Western Ontario, and an MBA from Kellogg School of Management. Along with the appointment of Suh, Doolan and Bedford, Andy O'Brien and Barrington Miller have stepped down from their respective positions on the Company's Board of Directors. O'Brien will remain the Company's Chief Performance Officer and Miller will remain an advisor to the Company. Cizzle Brands' Founder, Chairman, and Chief Executive Officer John Celenza commented, 'Evolution is a part of every company, and for us at Cizzle that evolution is happening lightning fast. Over the course of the last year, we've launched two hugely respected brands in CWENCH Hydration and Spoken Nutrition, gained distribution in over 3,300 points of sale, generated over $13M in revenue and raised over $20M. With our most recent financing complete, we're ready for the next stage of our growth which means bringing a new group of elite players to the team. With Ndamukong, we're accelerating the impact we're having on professional sports and further building our brand presence in the US. With the addition of Mike and Geoff we're getting more disciplined in operationalizing our growth. As Cizzle Brands further establishes its market position as a leader in the sports nutrition and hydration space, these additions will help position us to build upon the success we have realized to date and execute the next steps in our playbook for meaningful business growth and long-term value creation for shareholders.' About Cizzle Brands Corporation Cizzle Brands Corporation is a sports nutrition company that is elevating the game in health and wellness. Through extensive collaboration and testing with leading athletes and trainers across several elite sports, Cizzle Brands has launched two leading product lines in the sports nutrition category: (i) CWENCH Hydration™, a better-for-you sports drink that is now carried in over 3,300 locations in Canada, the United States, and Europe; and (ii) Spoken Nutrition, a premium brand of athlete-grade nutraceuticals that carry the prestigious NSF Certified for Sport® qualification. All Cizzle Brands products are designed to help people achieve their best in both competitive sports and in living a healthy, vibrant, active lifestyle. For more information about Cizzle Brands, please visit: For more information about CWENCH Hydration™, please visit: On behalf of the Board of Directors of the Company, CIZZLE BRANDS CORPORATION 'John Celenza' John Celenza, Founder, Chairman, and Chief Executive Officer CAUTIONARY NOTE REGARDING FORWARD-LOOKING INFORMATION This news release contains "forward-looking information" which may include, but is not limited to, information with respect to the activities, events or developments that the Company expects or anticipates will or may occur in the future, such as, but not limited to the ability to attract and retain key employees, advisors and directors. Such forward-looking information is often, but not always, identified by the use of words and phrases such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Forward looking information involves known and unknown risks, uncertainties and other risk factors which may cause the actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such risks include risks related to increased competition and current global financial conditions, access and supply risks, reliance on key personnel, operational risks, regulatory risks, financing, capitalization and liquidity risks. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company undertakes no obligation, except as otherwise required by law, to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors change.

Knight Therapeutics Reports Second Quarter 2025 Results
Knight Therapeutics Reports Second Quarter 2025 Results

Yahoo

time34 minutes ago

  • Yahoo

Knight Therapeutics Reports Second Quarter 2025 Results

MONTREAL, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or 'the Company'), a pan-American (ex-US) specialty pharmaceutical company, today reported financial results for its second quarter ended June 30, 2025. All currency amounts are in thousands except for share and per share amounts. All currencies are Canadian unless otherwise specified. Q2-25 Highlights Financial results Revenues were $107,358, an increase of $11,785 or 12% over the same period in prior year. Gross margin was $44,831 or 42% of revenues compared to $47,337 or 50% of revenues in the same period in prior year. The decrease was mainly driven by the impact of the hyperinflation accounting in Argentina. Operating loss was $3,669 compared to an operating income of $4,494 in the same period in prior year. Net loss was $12,622, compared to a net loss of $1,942 in the same period in prior year. Loss per share was $0.13, compared to a loss per share of $0.02 in the same period in prior year. Cash inflow from operations was $20,252, compared to cash outflows from operations of $1,086 in the same period in prior year. Non-GAAP measures Adjusted Revenues1 were $108,541, an increase of $14,420 or 15% or $18,867 or 21% on a constant currency1 basis. Innovative promoted product portfolio delivered an organic growth of 15% on a constant currency1 basis during the six-month period ending June 30, 2025. Adjusted Gross margin1 was $49,431 or 46% of Adjusted Revenues1 compared to $45,281 or 48% of Adjusted Revenues1 in the same period in prior year. The decrease in the Adjusted Gross margin1, as a percentage of Adjusted Revenues1, was mainly due to product mix. Adjusted EBITDA1 was $15,507, a decrease of $237 or 2% over the same period in prior year. Adjusted EBITDA per share1 was $0.16 and remained flat over the same period in prior year. Corporate developments Entered into a revolving credit facility of US$50,000 with National Bank of Canada ("NBC"), of which $60,000 was withdrawn to fund a portion of the Paladin acquisition. Settled the Synergy loan agreement and collected $13,758 [US$10,000] in cash and received warrants with a fair value of $1,116 [US$811]. Shareholders re-elected Jonathan Ross Goodman, Samira Sakhia, James C. Gale, Robert N. Lande, Michael J. Tremblay, Nicolás Sujoy, and Janice Murray on the Board of Directors. Products Added profitable and growth assets and expanded our portfolio by over fifty products including five pipeline and early launch stage assets over the past six months. Executed an asset purchase agreement with Paladin Pharma Inc., to acquire the Paladin business. At closing, Knight paid $84,544 and an additional $22,341 for inventory. The payment at closing was reduced by a holdback of $15,458 that may be released upon certain conditions. Furthermore, Knight may pay up to an additional US$15,000 upon achieving certain sales milestones. Entered into exclusive license and supply agreements with Sumitomo to commercialize Myfembree® (relugolix/estradiol/norethindrone acetate), Orgovyx® (relugolix), vibegron, and an asset purchase agreement to acquire certain mature products in Canada for an upfront of $25,400. Knight may pay up to an additional $15,750 if certain sales milestones are met. Submitted Crexont® (carbidopa and levodopa) for regulatory approval in Canada and Mexico. Submitted Minjuvi® (tafasitamab) for follicular lymphoma for ANVISA approval in Brazil. Obtained regulatory approval for Pemazyre® (pemigatinib) in Argentina. Obtained regulatory approval for Rembre® (dasatinib) in Chile. Re-launched Onicit® IV (palonosetron) in Mexico and Brazil. Subsequent to quarter-end Completed the NCIB launched in July 2024 with a total purchase of 2,019,906 common shares at an average price of $5.48 for aggregate cash consideration of $11,065. Amended the Supply and Distribution Agreement with Incyte to add the exclusive rights to distribute ZYNYZ® (retifanlimab) and NIKTIMVO™ (axatilimab) in Latin America. Collected strategic loan receivable with a life sciences company for $3,784 (US$2,771). Released $3,913 of the holdback amount payable under the Asset Purchase Agreement with Paladin to settle certain liabilities. 'I am excited to announce that for the first half of 2025, we achieved a record-high adjusted revenues1 of $197 million, a growth of 9% and an adjusted EBITDA1 of approximately $28 million. Our innovative promoted product portfolio delivered an organic growth of 15% on a constant currency1 basis during the same period. In addition, we have added over fifty products with the Paladin and Sumitomo transactions. These profitable portfolios included seven pipeline and early launch assets that will further accelerate the growth trajectory of our Canadian business. In addition, we secured a revolving credit facility with NBC ensuring we remain well positioned to continue to transact and execute on our mission to acquire, in-license, develop, and commercialize pharmaceutical products in Latin America and Canada,' said Samira Sakhia, President and CEO of Knight Therapeutics Inc. _______________________________1 Adjusted Revenues, revenues at constant currency, Adjusted Gross Margin, Adjusted EBITDA and Adjusted EBITDA per share are non-GAAP measures and do not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to section - Financial Results under Non-GAAP measures for additional FINANCIAL RESULTS REPORTED UNDER IFRS[In thousands of Canadian dollars] Change Change Q2-25 Q2-24 $1 %2 YTD-25 YTD-24 $1 %2 Revenues 107,358 95,573 11,785 12 % 195,434 182,177 13,257 7 % Gross margin 44,831 47,337 (2,506 ) 5 % 79,697 89,036 (9,339 ) 10 % Gross margin % 50 % 49 % Selling and marketing 15,674 13,264 (2,410 ) 18 % 29,598 25,913 (3,685 ) 14 % General and administrative 15,814 12,099 (3,715 ) 31 % 28,033 22,637 (5,396 ) 24 % Research and development 6,281 5,806 (475 ) 8 % 11,067 10,786 (281 ) 3 % Amortization of intangible assets 10,731 11,674 943 8 % 20,205 22,546 2,341 10 % Operating expenses 48,500 42,843 (5,657 ) 13 % 88,903 81,882 (7,021 ) 9 % Operating (loss) income (3,669 ) 4,494 (8,163 ) 182 % (9,206 ) 7,154 (16,360 ) 229 % Net loss (12,622 ) (1,942 ) (10,680 ) 550 % (10,437 ) (6,488 ) (3,949 ) 61 % 1 A positive variance represents a positive impact to net income (loss) and a negative variance represents a negative impact to net income (loss).2 Percentage change is presented in absolute values. Revenues: For the quarter ended June 30, 2025, revenues increased by $11,785 or 12% compared to the same period in prior year, which included an offset of $2,635 due the Hyperinflation Impact1. Excluding IAS 29, the increase was $14,420 or 15% and $18,867 or 21% on a constant currency2 basis. The increase in revenues was driven by our key promoted products which grew by $13,506 or 20% on a constant currency2 basis, purchasing patterns of certain products as well incremental revenues of $2,437 from Paladin and Sumitomo Transactions, partly offset by declines in our mature products and the depreciation of select LATAM currencies. Our revenues by therapeutic area is as follows: Change Therapeutic Area Q2-25 Q2-24 $ % Oncology/Hematology 34,914 36,430 (1,516 ) 4 % Infectious Diseases 44,808 38,243 6,565 17 % Other Specialty 27,636 20,900 6,736 32 % Total 107,358 95,573 11,785 12 % _______________________________1 The Hyperinflation Impact is due to the application of IAS 29 in Argentina. Refer to section - Hyperinflation for additional details.2 Revenues at constant currency is a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to section - Financial Results under Non-GAAP measures for additional details. The increase in revenues is explained by the following: Oncology/Hematology: Excluding the termination of a non-strategic distribution agreement in Colombia in December 2024, for the quarter ended June 30, 2025, the oncology/hematology portfolio decreased by $537 or 2%, which included an offset of $1,340 due to the Hyperinflation Impact1. Excluding IAS 29, the oncology/hematology portfolio increased by $803 or 2%. The revenues from our key promoted products increased by $2,916 or 16% on a constant currency2 basis driven by the growth of Akynzeo®, the launch of Minjuvi® and the addition of Orgovyx® and Onicit®. This growth was offset by a decline in our mature and branded generics products due to their lifecycle and the depreciation of select LATAM currencies. Infectious Diseases: For the quarter ended June 30, 2025, the infectious diseases portfolio increased by $6,565 or 17%, which included an offset of $909 due to the Hyperinflation Impact1. Excluding IAS 29, the infectious diseases portfolio increased by $7,474 or 20% and $9,480 or 26% on constant currency2 basis. The increase was due to the growth of Cresemba®, additional Ambisome® deliveries to the Ministry of Health in Brazil ("MOH"), offset by purchasing patterns of certain products. The Company signed the following contracts with the MOH for Ambisome®, with the following deliveries: Contract Delivered Year Total YTD-25 2024 2023 2022 Total 2022 $34,600 — $2,400 $25,200 $7,000 $34,600 2024 $22,400 — $22,400 — — $22,400 2025 $32,229 $32,229 — — — $32,229 Total $89,229 $32,229 $24,800 $25,200 $7,000 $89,229 1Amount expected to be delivered to the MOH in 2025. Q2-25 vs Q2-24 and YTD-25 vs YTD-24 ContractYear Q2-25 Q2-24 YTD-25 YTD-24 2022 — — — $2,400 2024 — $8,900 — $15,700 2025 $19,529 — $32,229 — Total $19,529 $8,900 $32,229 $18,100 Other Specialty: For the quarter ended June 30, 2025, the other specialty portfolio increased by $6,736 or 32%, which included an offset of $386 due to the Hyperinflation Impact1. Excluding IAS 29, the other specialty portfolio increased by $7,122 or 34% and $8,166 or 42% on constant currency2 basis driven by the launch of Imvexxy® and Bijuva®, incremental revenues from the Paladin and Sumitomo Transactions and purchasing patterns of certain customers. _______________________________1 The Hyperinflation Impact is due to the application of IAS 29 in Argentina. Refer to section - Hyperinflation for additional details.2 Revenues at constant currency is a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to section - Financial Results under Non-GAAP measures for additional details. Gross margin: For the quarter ended June 30, 2025, gross margin, as a percentage of revenues, was 42% compared to 50% in Q2-24. Excluding IAS 29, gross margin, as a percentage of Adjusted Revenues1 was 46% compared to 48% in Q2-24. The decrease in the gross margin % is mainly explained by the product mix as well as severance costs of $626 related to the closure of Knight´s HIV and respiratory manufacturing facility in Argentina. All the key products produced in that facility were transferred to certain contract manufacturers. Selling and marketing ('S&M') expenses: For the quarter ended June 30, 2025, S&M expenses increased by $2,410 or 18%, which included an offset of $627 due to the Hyperinflation Impact2. Excluding IAS 29, S&M expenses increased by $3,037 or 23%. The increase was mainly driven by an expansion in our sales and commercial structure behind the launches of Minjuvi® in Mexico and Jornay PM® in Canada as well as an increase in marketing activities behind our key promoted products. In addition, the S&M expenses included incremental costs related to the Paladin Transaction executed in June 2025. General and administrative ('G&A') expenses: For the quarter ended June 30, 2025, G&A expenses increased by $3,715 or 31%, which included an offset of $611 due to the Hyperinflation Impact2. Excluding IAS 29, G&A increased by $4,326 or 37%. The increase is mainly driven by acquisition and transaction costs of $3,430 related to Paladin Transaction as well as an increase in share-based compensation as a result of the assessment of their vesting expectations. Research and development ('R&D') expenses: For the quarter ended June 30, 2025, R&D expenses increased by $475 or 8%, which included an offset of $427 due to the Hyperinflation Impact2. Excluding IAS 29, R&D expenses increased by $902 or 16%. The increase is due to incremental expenses related to the portfolio of products added from the Paladin Transaction. Net lossFor the quarter ended June 30, 2025, the net loss was $12,622 compared to net loss of $1,942 for the same period in prior year. The variance mainly resulted from the above-mentioned items and (1) a net loss of $5,737 on the revaluation of financial assets measured at fair value through profit or loss in Q2-25 versus a net loss of $665 in the same period in prior year, (2) Other expense of $2,190 in Q2-25 driven by the repayment of the Synergy loan compared to a gain of $42 in Q2-24, (3) gain on hyperinflation of $893 in Q2-25 compared to a gain on hyperinflation of $2,084 in Q2-24, (4) a foreign exchange loss of $4,559 in Q2-25 mainly driven by the appreciation of CAD vs USD, compared to a foreign exchange loss of $5,542 in Q2-24 mainly driven by unrealized losses on intercompany balances due to the depreciation of the BRL and COP vs USD, and (5) an income tax recovery of $2,988 in Q2-25 compared to an income tax expense of $2,655 in Q2-24. _______________________________1 Adjusted revenue is a non-GAAP measures and do not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to section - Financial Results under Non-GAAP measures for additional details.2 The Hyperinflation Impact is due to the application of IAS 29 in Argentina. Refer to section - Hyperinflation for additional BALANCE SHEET ITEMS[In thousands of Canadian dollars] Change June 30, 2025 December 31, 2024 $ % Cash, cash equivalents and marketable securities 91,191 142,331 (51,140 ) 36 % Trade and other receivables 149,049 154,518 (5,469 ) 4 % Inventories 148,652 102,698 45,954 45 % Financial assets 103,186 133,932 (30,746 ) 23 % Intangible assets 384,070 283,612 100,458 35 % Accounts payable and accrued liabilities 109,972 83,173 26,799 32 % Bank loans 97,665 43,385 54,280 125 % Cash, cash equivalents and marketable securities: As at June 30, 2025, Knight had $91,191 in cash, cash equivalents and marketable securities, a decrease of $51,140 or 36% as compared to December 31, 2024. The decrease is mainly driven by payment of $130,985 for the Paladin and Sumitomo Transactions, repayment of principal and interest on bank loans by $8,829, partially offset by $60,000 withdrawn from the credit facility with NBC, cash inflows from operations of $23,922 and the collection of the Synergy loan of $13,758. Trade and other receivables: As at June 30, 2025, Trade and other receivables were $149,049, a decrease of $5,469 or 4%, as compared to December 31, 2024, mainly due to the timing of collections from certain customers. Inventories: As at June 30, 2025, Inventory were $148,652, an increase of $45,954 or 45%, as compared to December 31, 2024, mainly due to timing of purchases as well as investments on our new product launches and the inventory acquired as part of Paladin Transaction. Financial assets: As at June 30, 2025, financial assets were $103,186, a decrease of $30,746 or 23%, as compared to December 31, 2024, mainly driven by the settlement of the loan agreement with Synergy and net decrease in the value of our investments in funds. Intangible assets: As at June 30, 2025, intangible assets were $384,070, an increase of $100,458 or 35%, as compared to December 31, 2024, mainly due to the recognition of the fair value of intangible assets acquired in the Paladin Transaction for $93,088 and the Sumitomo Transaction for $29,708, offset by amortization, foreign exchange revaluation and the de-recognition of certain milestones not expected to be met. Accounts payable and accrued liabilities: As at June 30, 2025, accounts payable and accrued liabilities were $109,972, an increase of $26,799 or 32%, as compared to December 31, 2024, mainly driven by the purchase of inventory for our key promoted products. Bank Loans: As at June 30, 2025, bank loans were $97,665, an increase of $54,280 or 125%, as compared December 31, 2024, mainly due to the new credit facility with NBC with $60,000 withdrawn as at June 30, 2025, partly offset by net repayments of $4,954 and foreign exchange revaluation of $765. Product Updates Pemazyre® (pemigatinib) In Q2-25, Knight obtained the regulatory approval in Argentina for Pemazyre® for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy. Crexont® (carbidopa and levodopa) In Q2-25, Knight submitted Crexont® for approval in Canada and Mexico. Crexont® is a novel, oral formulation of carbidopa ("CD")/levodopa ("LD") extended-release capsules designed for the treatment of Parkinson's disease. Minjuvi® (tafasitamab) In Q2-25, Knight submitted Minjuvi® for ANVISA approval in Brazil for an additional indication in combination with rituximab and lenalidomide for the treatment of adult patients with previously treated follicular lymphoma (FL). Retifanlimab and axatilimab In July 2025, Knight expanded its relationship with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte, for the exclusive rights to distribute retifanlimab (sold as ZYNYZ® in the United States and Europe) and axatilimab (sold as NIKTIMVO™ in the United States) for Latin America. Retifanlimab is approved in the United States and Europe for the treatment of adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (MCC), a rare and aggressive type of skin cancer1. Retifanlimab is also approved by the U.S. Food and Drug Administration (FDA) in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC).1 In addition, the FDA approved retifanlimab as a single agent for the treatment of adult patients with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy.1 Axatilimab received FDA approval in August 2024 for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg.2 Chronic GVHD is a serious complication of allogeneic stem cell transplantation in which the donor's immune cells attack the recipient's tissues, potentially affecting multiple organs such as the skin, liver, lungs, and gastrointestinal tract. _______________________________1 Incyte Corporation. ZYNYZ (retifanlimab-dlwr) injection, for intravenous use: Full prescribing information. Retrieved July 24, 2025, from 2 Incyte Corporation. NIKTIMVO (axatilimab-csfr) injection, for intravenous use: Full prescribing information. Retrieved July 24, 2025, from Paladin Transaction On March 10, 2025, Knight entered into a definitive Asset Purchase Agreement to acquire the international business of Endo Operations Limited which was mainly its Canadian business operating as Paladin Pharma Inc. ("Paladin Transaction"). On June 17, 2025, Knight closed the Paladin Transaction upon receipt of customary regulatory approvals including anti-trust clearance in Canada. Knight paid $106,885 in cash including $22,341 for inventory. Knight held back $15,458 of which $10,000 may be released under specific conditions and the remaining $5,458 is expected to be used to settle certain liabilities. Furthermore, Knight may pay future contingent payments of up to US$15,000 upon achieving certain sales milestones. As at August 6, 2025, as part of Knight's integrations activities, Paladin's headcount has been reduced by approximately 25%. Sumitomo Transaction On June 5, 2025, Knight entered into exclusive license and supply agreements with Sumitomo Pharma America Inc. and its affiliates to commercialize Myfembree® (relugolix/estradiol/norethindrone acetate), Orgovyx® (relugolix) and vibegron in Canada, as well as an asset purchase agreement under which Knight acquired certain mature products ('Sumitomo Transaction'). Under the terms of the agreements, Knight acquired the exclusive rights to distribute, promote, market and sell the in-licensed and acquired products in Canada. The consideration for the Sumitomo Transaction included an upfront of $25,400 as well as certain future contingent sales milestones of up to $15,750. At closing, Knight held back $1,300 that may be released if certain conditions are met. Working capital line of credit with Citibank, N.A. In Q1-25, Knight closed an uncommitted working capital line of credit with Citibank, N.A. for a total amount of US$40,000 [$57,504]. On April 7, 2025, US$35,000 [$50,316] was withdrawn under this facility, at an interest rate of SOFR+2.30%. The line of credit was fully repaid in June 2025. Credit Facility with National Bank of Canada ("NBC")On June 17, 2025, Knight entered into a revolving credit facility with NBC for a total amount of US$50,000 [$68,215] ('Credit Facility'), of which $60,000 was withdrawn at closing to fund a portion of the Paladin Transaction. The Credit Facility is secured by Knight's assets held in Canada and has an initial term of 3 years, with the option to extend annually for additional one-year term. The Credit Facility is subject to customary covenants and stand-by fees for the undisbursed portion and can be drawn in USD or CAD at the SOFR or CORRA rate plus an applicable margin between 1.25% to 2.75% depending on Knight's debt leverage. In addition, NBC has launched a syndication process, and it is expected that the size of the credit facility will be increased to US$100 million plus an accordion of US$50M by the end of 2025. Financial Outlook1 For fiscal 2025, Knight has increased its financial guidance on revenues and now expects to generate between $410 million to $420 million in revenues up from $390 to $405 million. The adjusted EBITDA2 is expected to be approximately 13% of revenues. The increase in our revenues outlook is driven by the better performance in the first half of the year and the incremental revenues from the Sumitomo Transaction. The guidance is based on a number of assumptions, including but not limited to the following: no material impact on revenues due to the application of hyperinflation accounting for Argentina no revenues for business development transactions not completed as at August 6, 2025 no unforeseen termination to our license, distribution & supply agreements no interruptions in supply whether due to global supply chain disruptions or general manufacturing issues no new generic entrants on our key pharmaceutical brands no unforeseen changes to government mandated pricing regulations successful commercial execution on product listing arrangements with HMOs, insurers, key accounts, and public payers successful execution and uptake of newly launched products no material increase in provisions for inventory or trade receivables no significant variations of forecasted foreign currency exchange rates inflation remaining within forecasted ranges Should any of the assumptions differ, the financial outlook and the actual results may vary materially. Refer to the risks and assumptions referred to in the Forward-Looking Statements section of this news release for further details. _______________________________1 This forward looking information is based on assumptions specific to the nature of the Company's activities with regard to annual revenue growth considering industry information, expected market share, pricing assumptions, actions of competitors, sales erosion rates after the end of patent or other intellectual property rights protection, the timing of the entry of generic competition, the expected results of tenders, among other variables.2 Adjusted EBITDA is a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Refer to section Financial Results under Non-GAAP measures for additional details. Conference Call Notice Knight will host a conference call and audio webcast to discuss its second quarter ended June 30, 2025, today at 8:30 am ET. Knight cordially invites all interested parties to participate in this call. Date: Thursday, August 7, 2025Time: 8:30 a.m. ETTelephone: Toll Free: 1-888-699-1199 or International 1-416-945-7677Webcast: or WebcastThis is a listen-only audio webcast. Media Player is required to listen to the broadcast. Replay: An archived replay will be available for 30 days at About Knight Therapeutics Inc. Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight's Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.'s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at or Forward-Looking Statement This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.'s Annual Report and in Knight Therapeutics Inc.'s Annual Information Form for the year ended December 31, 2024 as filed on Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements whether because of new information or future events, except as required by law. CONTACT INFORMATION: Investor Contact: Knight Therapeutics Inc. Samira Sakhia Arvind Utchanah President & Chief Executive Officer Chief Financial Officer T: 514.484.4483 T. +598.2626.2344 F: 514.481.4116 Email: IR@ Email: IR@ Website: Website: HYPERINFLATION The Company applies IAS 29, Financial Reporting in Hyperinflation Economies, as the Company's Argentine subsidiary uses the Argentine Peso as its functional currency. IAS 29 requires that the financial statements of an entity whose functional currency is the currency of a hyperinflationary economy be adjusted based on an appropriate general price index to express the effects of inflation. After applying for the effects of hyperinflation, the statement of income (loss) is converted using the closing foreign exchange rate of the month. Revenues and operating expenses in the local currency, i.e. ARS, are restated from the month of the sales or the month in which the expense was incurred to the end of the reporting period using the inflation index during that period. The restatement calculation is performed on a year to date basis based on IAS29 ("Inflation Adjusted Figures"). For the six-month period ended June 30, 2025 and 2024, the Company applied the following inflation index for the restatement of each respective month. January February March April May June 2025 1.13 1.10 1.06 1.03 1.02 1.00 2024 1.49 1.32 1.19 1.09 1.05 1.00 Under IAS 29, the translation from the local currency, to the reporting currency is performed on the Inflation Adjusted Figures using the end of period rate at the reporting date. The Inflation Adjusted Figures were converted to CAD using the following quarter-end closing rates for each of the respective periods. Q2-25 Q2-24 ARS 874 666 Q2-25 Q2-24 YTD-25 YTD-24 ARS Variation %1 (17)% (4)% (22)% (9)% 1 Depreciation of ARS vs CAD during each period, calculated as follows: (End of period rate - Beginning of period rate) / Beginning of period rate. In Q2-25 and YTD-25 the inflation rate used for the hyperinflation adjustment on revenues and operating expenses of the Company's subsidiary in Argentina was lower than the ARS depreciation in the same period. For example, the revenues generated and operating expenses incurred in January 2025 were restated by applying an inflation index of 13% while the ARS to CAD depreciated by 22% in YTD-25. Consequently, this resulted in lower revenues and operating expenses reported under IAS 29 in CAD. Conversely, in Q2-24 and YTD-24 the inflation index was higher than the ARS depreciation which resulted in higher revenues and operating expenses reported under IAS 29 in CAD. Therefore, the hyperinflation accounting under IAS 29 resulted in a decrease in the reported revenues and operating expenses of the Company's subsidiary in Argentina in CAD in both Q2-25 and YTD-25 when compared to the same periods in prior year ("Hyperinflation Impact"). Under hyperinflation accounting, the cost of goods sold in the local currency, i.e. ARS, is restated using the inflation index from the purchase or manufacturing date to the end of the reporting period, and are converted to CAD using the respective quarter-end closing rates. In Q2-25 and YTD-25, the cumulative inflation index applied on the inventory sold was higher than the prior year periods, leading to higher cost of goods sold reported under IAS 29 in CAD and consequently a lower gross margin both in Q2-25 and YTD-25 compared to the same periods in prior year ("Gross Margin Hyperinflation Impact"). FINANCIAL RESULTS UNDER NON-GAAP MEASURES[In thousands of Canadian dollars] The Company discloses non-GAAP measures and ratios that do not have standardized meanings prescribed by IFRS. The Company believes that shareholders, investment analysts and other readers find such measures helpful in understanding the Company's financial performance. Non-GAAP financial measures and adjusted EBITDA per share ratio do not have any standardized meaning prescribed by IFRS and may not have been calculated in the same way as similarly named financial measures presented by other companies. The Company uses the following non-GAAP measures. [i] Financial results excluding the impacts of hyperinflation under IAS 29 The Company applies IAS 29, Financial Reporting in Hyperinflation Economies, as the Company's Argentine subsidiary used the Argentine Peso as their functional currency. IAS 29 requires that the financial statements of an entity whose functional currency is the currency of a hyperinflationary economy be adjusted based on an appropriate general price index to express the effects of inflation. Financial results under IFRS are adjusted to remove the impact of hyperinflation under IAS 29. The impact of hyperinflation under IAS 29 is calculated by applying an appropriate general price index to express the effects of inflation. After applying the effects of translation, the statement of income is converted using the closing foreign exchange rate of the month. The Company believes that financial results excluding the impact of hyperinflation under IAS 29 represents a useful measure to investors as they allow results to be viewed without those impacts, thereby facilitating the comparison of results period over period. The presentation of financial results excluding the impact of hyperinflation under IAS 29 is considered to be a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. The following tables reconcile the financial results under IFRS to financial results excluding the impact of hyperinflation under IAS 29. Q2-25 YTD-25 Reportedunder IFRS IAS 29Adjustment Excluding theImpacts ofIAS 29 Reportedunder IFRS IAS 29Adjustment Excluding theImpacts ofIAS 29 Revenues 107,358 1,183 108,541 195,434 1,086 196,520 Cost of goods sold 62,527 (3,417 ) 59,110 115,737 (9,582 ) 106,155 Gross margin 44,831 4,600 49,431 79,697 10,668 90,365 Gross margin (%) Expenses Selling and marketing 15,674 331 16,005 29,598 247 29,845 General and administrative 15,814 90 15,904 28,033 (547 ) 27,486 Research and development 6,281 198 6,479 11,067 220 11,287 Amortization of intangible assets 10,731 — 10,731 20,205 — 20,205 Operating (loss) income (3,669 ) 3,981 312 (9,206 ) 10,748 1,542 Q2-24 YTD-24 Reportedunder IFRS IAS 29Adjustment Excluding theImpact ofIAS 29 Reportedunder IFRS IAS 29Adjustment Excluding theImpact ofIAS 29 Revenues 95,573 (1,452 ) 94,121 182,177 (2,260 ) 179,917 Cost of goods sold 48,236 604 48,840 93,141 799 93,940 Gross margin 47,337 (2,056 ) 45,281 89,036 (3,059 ) 85,977 Gross margin (%) 50 % 48 % 49 % 48 % Expenses Selling and marketing 13,264 (296 ) 12,968 25,913 (452 ) 25,461 General and administrative 12,099 (521 ) 11,578 22,637 (847 ) 21,790 Research and development 5,806 (229 ) 5,577 10,786 (369 ) 10,417 Amortization of intangible assets 11,674 25 11,699 22,546 (1 ) 22,545 Operating income (loss) 4,494 (1,035 ) 3,459 7,154 (1,390 ) 5,764 Select financial results excluding the impact of hyperinflation under IAS 291 Change Change Q2-25 Q2-24 $ % YTD-25 YTD-24 $ % Adjusted Revenues 108,541 94,121 14,420 15 % 196,520 179,917 16,603 9 % Cost of goods sold 59,110 48,840 (10,270 ) 21 % 106,155 93,940 (12,215 ) 13 % Adjusted Gross margin 49,431 45,281 4,150 9 % 90,365 85,977 4,388 5 % Adjusted Gross margin (%) 48 % 48 % Expenses Selling and marketing 16,005 12,968 (3,037 ) 23 % 29,845 25,461 (4,384 ) 17 % General and administrative 15,904 11,578 (4,326 ) 37 % 27,486 21,790 (5,696 ) 26 % Research and development 6,479 5,577 (902 ) 16 % 11,287 10,417 (870 ) 8 % Amortization of intangible assets 10,731 11,699 968 8 % 20,205 22,545 2,340 10 % Operating (loss) income 312 3,459 (3,147 ) 91 % 1,542 5,764 (4,222 ) 73 % Adjusted EBITDA1 15,507 15,744 (237 ) 2 % 27,620 29,333 (1,713 ) 6 % Adjusted EBITDA1 (%) 17 % 16 % Adjusted EBITDA per share1 0.16 0.16 — — % 0.28 0.29 (0.01 ) 3 % 1 Adjusted EBITDA, Adjusted EBITDA per share and financial results excluding the impact of IAS 29 are non-GAAP measures and do not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Adjusted Revenues1 by Therapeutic Area Change Change Therapeutic Area Q2-25 Q2-24 $ % YTD-25 YTD-24 $ % Oncology/Hematology 35,448 35,624 (176 ) — % 67,124 66,467 657 1 % Infectious Diseases 45,299 37,825 7,474 20 % 81,740 75,888 5,852 8 % Other Specialty 27,794 20,672 7,122 34 % 47,656 37,562 10,094 27 % Total 108,541 94,121 14,420 15 % 196,520 179,917 16,603 9 % 1 Excluding the impact of hyperinflation under IAS 29. Adjusted Revenues is a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. [ii] Financial results at constant currency Financial results at constant currency are obtained by translating the prior period revenues and financial results from the functional currencies to CAD using the conversion rates in effect during the current period. Furthermore, with respect to Argentina, the Company excludes the impact of hyperinflation and translates the revenues and results at the average exchange rate in effect for each of the periods. The Company believes that financial results at constant currency represents a useful measure to investors because it eliminates the effect that foreign currency exchange rate fluctuations may have on period-to-period comparability given the volatility in foreign currency exchange markets and therefore, provides greater transparency to the underlying performance of our consolidated financial results. The presentation of revenues and financial results under constant currency is considered to be a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. The following tables are reconciliations of financial results under IFRS to financial results and financial results at constant currency. Q2-24 YTD-24 Excluding theimpact ofIAS 291 ConstantCurrencyAdjustment ConstantCurrency Excluding theimpact ofIAS 291 ConstantCurrencyAdjustment ConstantCurrency Adjusted Revenues 94,121 (4,447 ) 89,674 179,917 (8,895 ) 171,022 Cost of goods sold 48,840 (2,435 ) 46,405 93,940 (5,075 ) 88,865 Adjusted Gross margin 45,281 (2,012 ) 43,269 85,977 (3,820 ) 82,157 Adjusted Gross margin (%) 48 % 48 % 48 % 48 % Expenses Selling and marketing 12,968 (528 ) 12,440 25,461 (990 ) 24,471 General and administrative 11,578 (185 ) 11,393 21,790 (244 ) 21,546 Research and development 5,577 (164 ) 5,413 10,417 (277 ) 10,140 Amortization of intangible assets 11,699 85 11,784 22,545 573 23,118 Operating income (loss) 3,459 (1,220 ) 2,239 5,764 (2,882 ) 2,882 1Refer to Subsection - [i] Financial results excluding the impact of hyperinflation under IAS 29 for additional details. Select financial results at Constant Currency1 Three-month period ended June 30, Six-month period ended June 30, Excluding impact of IAS 29 ConstantCurrency1 Change ConstantCurrency1 Change 2025 2024 $ % 2025 2024 $ % Adjusted Revenues 108,541 89,674 18,867 21 % 196,520 171,022 25,498 15 % Cost of goods sold 59,110 46,405 (12,705 ) 27 % 106,155 88,865 (17,290 ) 19 % Adjusted Gross margin 49,431 43,269 6,162 14 % 90,365 82,157 8,208 10 % Adjusted Gross margin (%) 48 % 48 % Expenses Selling and marketing 16,005 12,440 (3,565 ) 29 % 29,845 24,471 (5,374 ) 22 % General and administrative 15,904 11,393 (4,511 ) 40 % 27,486 21,546 (5,940 ) 28 % Research and development 6,479 5,413 (1,066 ) 20 % 11,287 10,140 (1,147 ) 11 % Amortization of intangible assets 10,731 11,784 1,053 9 % 20,205 23,118 2,913 13 % Operating income (loss) 312 2,239 (1,927 ) 86 % 1,542 2,882 (1,340 ) 46 % Adjusted EBITDA1 15,507 14,606 901 6 % 27,620 27,023 597 2 % Adjusted EBITDA1 (%) 16 % 16 % Adjusted EBITDA per share1 0.16 0.14 0.01 8 % 0.28 0.27 0.01 4 % 1 EBITDA, Adjusted EBITDA, Adjusted EBITDA per share and financial results at constant currency are a non-GAAP measures and do not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. Adjusted Revenues at Constant Currency1 by Therapeutic Area Three-month period ended June 30, Six-month period ended June 30, Excluding impact of IAS 29 ConstantCurrency1 ConstantCurrency1 Innovative 2025 2024 $ % 2025 2024 $ % Oncology/Hematology 35,448 34,227 1,221 4 % 67,124 64,067 3,057 5 % Infectious Diseases 45,299 35,819 9,480 26 % 81,740 71,160 10,580 15 % Other Specialty 27,794 19,628 8,166 42 % 47,656 35,795 11,861 33 % Total 108,541 89,674 18,867 21 % 196,520 171,022 25,498 15 % 1 Adjusted Revenues at constant currency is a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. [iii] Adjusted Gross MarginAdjusted Gross Margin is defined as revenues less cost of goods sold, excluding the impact of hyperinflation under IAS 29. The Company believes that Adjusted Gross Margin represents a useful measure to investors as allow Gross Margin to be viewed without the impact of hyperinflation under IAS 29, thereby facilitating the comparison period over period. The presentation of Adjusted Gross Margin is considered to be a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. [iv] EBITDA EBITDA is defined as operating income or loss adjusted to exclude amortization and impairment of non-current assets, depreciation, but to include costs related to leases. The Company believes that EBITDA represents a useful measure to investors to assess profitability and measure the Company's ability to generate liquidity through operating activities. The presentation of EBITDA is considered to be a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. [v] Adjusted EBITDA Adjusted EBITDA is defined as EBITDA adjusted for the impact of IAS 29 (accounting under hyperinflation), acquisition and transaction costs, the impact in cost of goods sold of the difference between the fair value of inventory acquired and the cost paid in a transaction accounted under IFRS 3 (business combination) ("Step-Up Expense") and non-recurring expenses. The Company believes that Adjusted EBITDA represents a useful measure to investors to assess profitability and measure the Company's ability to generate liquidity through operating activities. The Company believes that Adjusted EBITDA represents a useful measure to investors to assess profitability and measure the Company's ability to generate liquidity through operating activities, without the impact of hyperinflation under IAS 29, acquisition and transaction costs, Step-Up Expense and non-recurring expenses, thereby facilitating the comparison period over period. The presentation of adjusted EBITDA is considered to be a non-GAAP measure and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. The following table is a reconciliation of operating income (loss) to EBITDA and adjusted EBITDA: Change Change Q2-25 Q2-24 $ % YTD-25 YTD-24 $ % Operating income (loss) (3,669 ) 4,494 (8,163 ) 182 % (9,206 ) 7,154 (16,360 ) 229 % Adjustments to operating income (loss): Amortization of intangible assets 10,731 11,674 (943 ) 8 % 20,205 22,546 (2,341 ) 10 % Depreciation of property, plant and equipment and ROU assets 1,407 1,495 (88 ) 6 % 3,517 3,204 313 10 % Lease payments (1,063 ) (982 ) (81 ) 8 % (2,185 ) (1,864 ) (321 ) 17 % EBITDA 7,406 16,681 (9,275 ) 56 % 12,331 31,040 (18,709 ) 60 % Impact of IAS 29 3,896 (1,040 ) 4,936 475 % 10,042 (1,810 ) 11,852 655 % Acquisition and transaction costs 3,419 103 3,316 — % 4,461 103 4,358 — % Step-Up Expense 160 — 160 — % 160 — 160 — % Other non-recurring expenses 626 — 626 — % 626 — 626 — % Adjusted EBITDA 15,507 15,744 (237 ) 2 % 27,620 29,333 (1,713 ) 6 % Adjusted EBITDA per share 0.16 0.16 — — % 0.28 0.29 (0.01 ) 3 % For the quarter ended June 30, 2025, adjusted EBITDA decreased by $237 or 2%. The decrease was driven by lower gross margin and higher operating expenses related to an increase in our promotional activities behind the of IAS 29 Impact of hyperinflation accounting under IAS 29 over the operating income (loss). Acquisition and transaction costs Non-capitalizable acquisition and transaction costs relate to costs incurred on legal, consulting and advisory fees for the acquisitions. Step-Up Expense Step-up expense relates to the impact in cost of goods sold of the difference between the fair value of inventory acquired and the cost paid in a transaction accounted under IFRS 3 - Business Combinations, when the inventory acquired as part of the transaction is sold. Other non-recurring expenses Other non-recurring expenses relate to expenses incurred by the Company that are not due to, and are not expected to occur in, the ordinary course of business. [vi] Adjusted EBITDA per share Adjusted EBITDA per share is defined as Adjusted EBITDA over number of common shares outstanding at the end of the respective period. The Company believes that Adjusted EBITDA per share represents a useful measure to investors to assess profitability and measure the Company's ability to generate liquidity through operating activities on a per common share basis, without the impact of hyperinflation under IAS 29, acquisition and transaction costs, Step-Up Expense and non-recurring expenses, thereby facilitating the comparison period over period. The presentation of adjusted EBITDA per share is considered to be a non-GAAP ratio and does not have any standardized meaning under GAAP. As a result, the information presented may not be comparable to similar measures presented by other companies. The Company calculated adjusted EBITDA per share as follows: Q2-25 Q2-24 YTD-25 YTD-24 Adjusted EBITDA 15,507 15,744 27,620 29,333 Adjusted EBITDA per share 0.16 0.16 0.28 0.29 Number of common shares outstanding at period end (in thousands) 99,653 101,327 99,653 101,327 INTERIM CONSOLIDATED BALANCE SHEETS[In thousands of Canadian dollars][Unaudited] As at June 30, 2025 December 31, 2024 ASSETS Current Cash and cash equivalents 77,816 80,106 Marketable securities 13,375 62,225 Trade receivables 97,289 105,196 Other receivables 5,033 4,339 Inventories 148,652 102,698 Prepaids and deposits 7,350 7,744 Other current financial assets 25,230 30,506 Income taxes receivable 5,383 3,999 Total current assets 380,128 396,813 Prepaids and deposits 8,681 7,217 Right-of-use assets 7,025 5,912 Property, plant and equipment 13,433 14,110 Intangible assets 384,070 283,612 Goodwill 90,825 86,477 Other financial assets 77,956 103,426 Deferred tax assets 29,099 21,247 Other long-term receivables 46,727 44,983 Total non-current assets 657,816 566,984 Total assets 1,037,944 963,797 INTERIM CONSOLIDATED BALANCE SHEETS (continued)[In thousands of Canadian dollars][Unaudited] As at June 30, 2025 December 31, 2024 LIABILITIES AND SHAREHOLDERS' EQUITY Current Accounts payable and accrued liabilities 104,936 78,345 Lease liabilities 3,390 2,640 Other liabilities 18,408 1,876 Bank loans 18,823 17,486 Income taxes payable 313 213 Other balances payable 8,076 10,688 Total current liabilities 153,946 111,248 Accounts payable and accrued liabilities 5,036 4,828 Lease liabilities 3,688 3,434 Bank loans 78,842 25,899 Other balances payable 30,323 19,443 Deferred tax liabilities 3,052 3,840 Total liabilities 274,887 168,692 Shareholders' equity Share capital 532,642 534,266 Warrants — 117 Contributed surplus 27,889 25,708 Accumulated other comprehensive income 58,317 80,220 Retained earnings 144,209 154,794 Total shareholders' equity 763,057 795,105 Total liabilities and shareholders' equity 1,037,944 963,797 INTERIM CONSOLIDATED STATEMENTS OF INCOME (LOSS)[In thousands of Canadian dollars, except for share and per share amounts][Unaudited] Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 Revenues 107,358 95,573 195,434 182,177 Cost of goods sold 62,527 48,236 115,737 93,141 Gross margin 44,831 47,337 79,697 89,036 50 % 49 % Expenses Selling and marketing 15,674 13,264 29,598 25,913 General and administrative 15,814 12,099 28,033 22,637 Research and development 6,281 5,806 11,067 10,786 Amortization of intangible assets 10,731 11,674 20,205 22,546 Operating (loss) income (3,669 ) 4,494 (9,206 ) 7,154 Interest income on financial instruments measured at amortized cost (2,011 ) (1,960 ) (3,849 ) (4,096 ) Other interest income (15 ) (624 ) (31 ) (1,129 ) Interest expense 2,374 2,284 4,130 4,861 Other expense (income) 2,190 (42 ) 2,330 (211 ) Net loss on financial assets measured at fair value through profit or loss 5,737 665 6,682 16,932 Foreign exchange gain 4,559 5,542 (992 ) 3,608 Gain on hyperinflation (893 ) (2,084 ) (1,467 ) (6,380 ) (Loss) Income before income taxes (15,610 ) 713 (16,009 ) (6,431 ) Income taxes Current 134 1,245 669 2,914 Deferred (3,122 ) 1,410 (6,241 ) (2,857 ) Income tax (recovery) expense (2,988 ) 2,655 (5,572 ) 57 Net loss for the period (12,622 ) (1,942 ) (10,437 ) (6,488 ) Basic and diluted net loss per share (0.13 ) (0.02 ) (0.10 ) (0.06 ) Basic and diluted weighted average number of common shares outstanding 99,629,927 101,330,154 99,635,582 101,251,374 INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS[In thousands of Canadian dollars][Unaudited] Three months ended June 30, Six months ended June 30, 2025 2024 2025 2024 OPERATING ACTIVITIES Net income (loss) for the period (12,622 ) (1,942 ) (10,437 ) (6,488 ) Adjustments reconciling net income to operating cash flows: Depreciation and amortization 12,138 13,169 23,722 25,750 Net loss on financial instruments 5,737 665 6,682 16,932 Unrealized foreign exchange (gain) loss (1,499 ) (4,124 ) (169 ) (6,329 ) Other operating activities 3,511 3,078 2,664 (3,646 ) 7,265 10,846 22,462 26,219 Changes in non-cash working capital and other items 12,987 (11,932 ) 1,460 3,576 Cash inflow (outflow) from operating activities 20,252 (1,086 ) 23,922 29,795 INVESTING ACTIVITIES Acquisition of Paladin (106,885 ) — (106,885 ) — Purchase of marketable securities (7,025 ) (41,625 ) (13,882 ) (77,922 ) Proceeds on maturity of marketable securities 21,990 69,674 61,627 91,990 Investment in funds (28 ) (1,072 ) (135 ) (1,203 ) Purchase of intangible assets (24,508 ) (16,735 ) (27,836 ) (26,817 ) Other investing activities 15,162 1,511 17,943 1,339 Cash inflow (outflow) from investing activities (101,294 ) 11,753 (69,168 ) (12,613 ) FINANCING ACTIVITIES Repurchase of common shares through Normal Course Issuer Bid (6 ) (1,242 ) (3,351 ) (1,242 ) Principal repayment of bank loans (54,818 ) (6,930 ) (56,404 ) (8,659 ) Proceeds from bank loans 109,394 747 111,203 1,292 Other financing activities (3,758 ) (3,937 ) (5,335 ) (5,650 ) Cash inflow (outflow) from financing activities 50,812 (11,362 ) 46,113 (14,259 ) (Decrease) Increase in cash and cash equivalents during the period (30,230 ) (695 ) 867 2,923 Cash and cash equivalents, beginning of the period 112,155 62,835 80,106 58,761 Net foreign exchange difference (4,109 ) (1,333 ) (3,157 ) (877 ) Cash and cash equivalents, end of the period 77,816 60,807 77,816 60,807 Cash and cash equivalents 77,816 60,807 77,816 60,807 Marketable securities 13,375 91,861 13,375 91,861 Total cash, cash equivalents and marketable securities 91,191 152,668 91,191 152,668 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store